181 related articles for article (PubMed ID: 11174837)
1. ACTH silent adenoma shrinking under cabergoline.
Petrossians P; Ronci N; Valdés Socin H; Kalife A; Stevenaert A; Bloch B; Tabarin A; Beckers A
Eur J Endocrinol; 2001 Jan; 144(1):51-7. PubMed ID: 11174837
[TBL] [Abstract][Full Text] [Related]
2. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
3. An unusual case of Cushing's syndrome due to bihormonal ACTH-prolactin secreting pituitary macroadenoma with rapid response to cabergoline.
Kunasegaran S; Croxson MS; Holdaway I; Murphy R
BMJ Case Rep; 2017 Aug; 2017():. PubMed ID: 28784879
[TBL] [Abstract][Full Text] [Related]
4. Dopamine receptor expression and function in corticotroph pituitary tumors.
Pivonello R; Ferone D; de Herder WW; Kros JM; De Caro ML; Arvigo M; Annunziato L; Lombardi G; Colao A; Hofland LJ; Lamberts SW
J Clin Endocrinol Metab; 2004 May; 89(5):2452-62. PubMed ID: 15126577
[TBL] [Abstract][Full Text] [Related]
5. Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to cabergoline therapy.
Vieira Neto L; Wildemberg LE; Moraes AB; Colli LM; Kasuki L; Marques NV; Gasparetto EL; de Castro M; Takiya CM; Gadelha MR
Clin Endocrinol (Oxf); 2015 May; 82(5):739-46. PubMed ID: 25418156
[TBL] [Abstract][Full Text] [Related]
6. Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotropin-secreting macroadenoma.
Miyoshi T; Otsuka F; Takeda M; Inagaki K; Suzuki J; Ogura T; Date I; Hashimoto K; Makino H
J Endocrinol Invest; 2004 Dec; 27(11):1055-9. PubMed ID: 15754738
[TBL] [Abstract][Full Text] [Related]
7. Effects of cabergoline in a pituitary adenoma secreting follicle-stimulating hormone.
Leese G; Jeffreys R; Vora J
Postgrad Med J; 1997 Aug; 73(862):507-8. PubMed ID: 9307745
[TBL] [Abstract][Full Text] [Related]
8. In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas.
Andersen M; Bjerre P; Schrøder HD; Edal A; Høilund-Carlsen PF; Pedersen PH; Hagen C
Clin Endocrinol (Oxf); 2001 Jan; 54(1):23-30. PubMed ID: 11167922
[TBL] [Abstract][Full Text] [Related]
9. Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT.
Pirker W; Riedl M; Luger A; Czech T; Rössler K; Asenbaum S; Angelberger P; Kornhuber J; Deecke L; Podreka I; Brücke T
J Nucl Med; 1996 Dec; 37(12):1931-7. PubMed ID: 8970508
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
Saveanu A; Gunz G; Guillen S; Dufour H; Culler MD; Jaquet P
Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
[TBL] [Abstract][Full Text] [Related]
11. Shrinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline.
Cannavò S; Bartolone L; Blandino A; Spinella S; Galatioto S; Trimarchi F
J Endocrinol Invest; 1999 Apr; 22(4):306-9. PubMed ID: 10342366
[TBL] [Abstract][Full Text] [Related]
12. Cabergoline modulation of alpha-subunits and FSH secretion in a gonadotroph adenoma.
Giusti M; Bocca L; Florio T; Foppiani L; Corsaro A; Auriati L; Spaziante R; Schettini G; Giordano G
J Endocrinol Invest; 2000; 23(7):463-6. PubMed ID: 11005271
[TBL] [Abstract][Full Text] [Related]
13. New medical approaches in pituitary adenomas.
Colao A; Di Sarno A; Marzullo P; Di Somma C; Cerbone G; Landi ML; Faggiano A; Merola B; Lombardi G
Horm Res; 2000; 53 Suppl 3():76-87. PubMed ID: 10971110
[TBL] [Abstract][Full Text] [Related]
14. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
15. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
[TBL] [Abstract][Full Text] [Related]
16. Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging?
de Herder WW; Reijs AE; Feelders RA; van Aken MO; Krenning EP; Tanghe HL; van der Lely AJ; Kwekkeboom DJ
Eur J Endocrinol; 2006 Nov; 155(5):717-23. PubMed ID: 17062888
[TBL] [Abstract][Full Text] [Related]
17. Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumours but do not recur more frequently.
Bradley KJ; Wass JA; Turner HE
Clin Endocrinol (Oxf); 2003 Jan; 58(1):59-64. PubMed ID: 12519413
[TBL] [Abstract][Full Text] [Related]
18. Comparison of ACTH secretion in Cushing's adenoma and clinically silent corticotroph adenoma by cell immunoblot assay.
Kojima Y; Suzuki S; Yamamura K; Ohhashi G; Yamamoto I
Endocr J; 2002 Jun; 49(3):285-92. PubMed ID: 12201210
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas.
Tateno T; Kato M; Tani Y; Oyama K; Yamada S; Hirata Y
Endocr J; 2009; 56(4):579-84. PubMed ID: 19318729
[TBL] [Abstract][Full Text] [Related]
20. Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists.
van der Pas R; Feelders RA; Gatto F; de Bruin C; Pereira AM; van Koetsveld PM; Sprij-Mooij DM; Waaijers AM; Dogan F; Schulz S; Kros JM; Lamberts SW; Hofland LJ
J Clin Endocrinol Metab; 2013 Dec; 98(12):E1880-90. PubMed ID: 24081741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
